VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Autologous CLL Tumor Cell Vaccine

Vaccine Information

Vaccine Name: Autologous CLL Tumor Cell Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Type: whole cell cancer vaccine
Status: Clinical trial
Host Species for Licensed Use: None
Antigen: CLL-associated antigens (Burkhardt et al., 2013)
Immunization Route: Other
Description: The vaccines consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT). (Burkhardt et al., 2013)

Host Response

References

Burkhardt et al., 2013: Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. The Journal of clinical investigation. 2013; 123(9); 3756-3765. [PubMed: 23912587].